11.4 Promotility Agents | Neonatology Academy

Bedside Purpose & One-Line Rule

Bedside Purpose

Prevent routine use of promotility medications for physiologic reflux, ordinary emesis, apnea of prematurity, or non-specific feeding intolerance.
Identify the narrow group of neonates who may benefit from a time-limited, specialist-directed motility trial after mechanical, infectious, metabolic, and feeding causes are addressed.
Standardize safe ordering, monitoring, stop criteria, and follow-up for erythromycin or amoxicillin/clavulanate when used for significant dysmotility.

One-Line Rule

Promotility agents are not first-line reflux therapy in the NICU. Consider them only after a documented dysmotility phenotype, optimization of feeds, exclusion of dangerous mimics, pharmacy safety review, and GI or intestinal rehabilitation discussion.

1. Core Bedside Messages

Clinical Question	Guideline Answer
Should prokinetics be used for routine neonatal GER?	No. GER is common and often non-acid in preterm infants; prokinetics should not be used for isolated regurgitation, apnea, bradycardia, desaturation, irritability, or feeding residuals without a broader diagnosis.
When might a motility agent be considered?	Rarely, for moderate-to-severe GI dysmotility, delayed gastric emptying, intestinal failure, short bowel syndrome, post-surgical dysmotility, or persistent inability to advance feeds after safer steps have failed.
Who should approve the trial?	Neonatology plus GI or the intestinal rehabilitation team, with pharmacy review for dose, formulation, interactions, QT risk, and local formulary rules.
What is the safest trial design?	Use one medication at a time, define the target symptom, document baseline feeding volume/growth/output, set a stop date, and stop if there is no objective benefit or any safety concern.
Which agents are generally avoided?	Metoclopramide, domperidone, cisapride, and bethanechol should not be routine NICU medications; they carry safety concerns and limited neonatal efficacy data.

2. Before Starting a Promotility Agent

Required Pre-Medication Checklist

Verify this is not NEC, SIP, obstruction, malrotation/volvulus, pyloric stenosis, sepsis, adrenal/metabolic disease, medication effect, cow milk protein allergy, or dysphagia/aspiration.
Review total fluids, mL/kg/day, kcal/oz, fortifier/osmolality, bolus volume, feed duration, tube tip position, stool/ostomy output, abdominal exam, and weight trend.
Optimize non-drug measures first: avoid overfeeding, reduce bolus volume if excessive, lengthen gavage delivery, consider smaller/more frequent feeds, support human milk, and involve feeding therapy when oral skills are involved.
For suspected gastric dysmotility, consider objective evidence such as persistent gastric retention pattern or gastric emptying study when clinically feasible.
Discuss plan with GI/intestinal rehabilitation and pharmacy before ordering.

Red Flag Assessment — Stop and Evaluate Before Any Prokinetic

Red Flag	Why It Changes the Plan	Action
Bilious emesis or acute distension	Possible obstruction, volvulus, NEC, or surgical abdomen.	NPO, decompression, urgent imaging/surgery.
Bloody stool, acidosis, thrombocytopenia, shock	Possible NEC/sepsis/intestinal ischemia.	NEC/sepsis pathway; do not mask with prokinetic.
Projectile non-bilious emesis, dehydration, hypochloremic alkalosis	Possible hypertrophic pyloric stenosis — especially with macrolide exposure.	Hold erythromycin; abdominal ultrasound and surgical evaluation.
QTc prolongation, arrhythmia, electrolyte derangement, bradycardia, cardiac disease	Macrolides and several motility agents may increase arrhythmia risk.	Correct electrolytes; obtain ECG/cardiology/pharmacy input; avoid high-risk drugs.
Progressive liver dysfunction	Macrolides are hepatically handled and may worsen cholestatic patterns.	Pharmacy/GI review; consider alternatives and close LFT monitoring.

3. Bedside Decision Pathway

Step	Question	Action
1	Is the infant unstable or are there surgical/NEC red flags?	Stop feeds, decompress stomach, obtain labs/imaging, start appropriate emergency pathway, and consult surgery.
2	Is this common physiologic reflux or mild prematurity-related emesis with growth?	Reassure, observe, avoid unnecessary tests/medications, and educate family.
3	Is there persistent feeding intolerance despite optimized feed volume, interval, duration, milk/formula choice, and tube position?	Review with dietitian and feeding team; evaluate for cow milk protein allergy, infection, electrolyte/metabolic causes, and dysphagia.
4	Is there evidence of clinically important dysmotility or intestinal failure?	Discuss with GI/intestinal rehabilitation and pharmacy; define objective trial endpoint.
5	Is erythromycin or amoxicillin/clavulanate chosen?	Use one agent only, start low, monitor response and safety, and stop if ineffective or adverse effects occur.
6	Will the infant go home on therapy?	Arrange GI/intestinal rehabilitation follow-up, medication-access review, caregiver education, and a reassessment/stop plan.

4. Medication Framework

Agent	Potential NICU Role	Suggested Use	Key Safety Points
Erythromycin ethylsuccinate	Motilin-receptor agonist for selected infants with significant delayed gastric emptying or moderate-to-severe dysmotility, usually after day 14.	Baylor: 5–10 mg/kg/dose enterally every 6 hr; start at lower dose and assess objective response.	Insufficient evidence for routine preterm feeding intolerance; QT prolongation, drug interactions, hepatotoxicity, tachyphylaxis, and infantile hypertrophic pyloric stenosis (IHPS) risk.
Amoxicillin/clavulanate	Rare option for significant small-bowel dysmotility, usually anatomic or functional intestinal failure.	Baylor: 10–20 mg/kg/dose enterally every 12 hr using the 80 mg/11.4 mg per mL suspension studied for pro-motility use.	Very limited literature; antibiotic exposure, diarrhea, candidiasis, rash, microbiome pressure, and antimicrobial-resistance concerns. Use only with intestinal rehabilitation/GI input.
Metoclopramide	Not recommended for routine GER/GORD or ordinary neonatal feeding intolerance.	Do not use routinely; if ever considered, requires GI/pharmacy discussion and explicit risk-benefit documentation.	Boxed warning for tardive dyskinesia; pediatric/neonatal concerns include extrapyramidal symptoms and methemoglobinemia risk.
Domperidone	Not a routine U.S. NICU option.	Avoid routine use.	Not FDA-approved for humans in the United States; associated with serious cardiac adverse events including arrhythmia, cardiac arrest, and sudden death.
Bethanechol / cisapride / other prokinetics	No routine role in common neonatal GER.	Avoid as first-line therapy; specialist-only if local expert pathway exists.	Limited neonatal evidence and important safety concerns; cisapride has major QT/arrhythmia interaction concerns, including with erythromycin.

5. Erythromycin Trial: How to Make It Safer

Domain	Recommended Practice
Eligibility	Persistent, clinically important dysmotility after day 14 of life, after optimization of feeds and exclusion of dangerous mimics. More defensible in intestinal failure, post-surgical dysmotility, or objectively delayed gastric emptying than in routine reflux.
Dose	Enteral erythromycin ethylsuccinate 5–10 mg/kg/dose every 6 hr. Start at the lower end, especially in fragile or high-risk infants.
Baseline checks	Review ECG/QTc if risk factors exist; correct K, Mg, and Ca; review bilirubin/liver enzymes; review all QT-prolonging and CYP3A-interacting medications.
Monitoring	Daily target endpoint: feed volume tolerated, emesis frequency, gastric output, abdominal exam, stool/ostomy output, weight, cardiorespiratory events, and caregiver/nursing observations.
Stop if…	No objective improvement, abdominal deterioration, diarrhea concerning for enterocolitis, new arrhythmia/QTc concern, cholestatic/hepatic concern, or new progressive non-bilious vomiting suggesting pyloric stenosis.
Duration	Use a time-limited trial with a predefined reassessment date. Avoid indefinite continuation; tachyphylaxis and adverse effects become more relevant with prolonged use.

IHPS risk reminder

Macrolide exposure in the neonatal period, especially in the first weeks of life, has been associated with infantile hypertrophic pyloric stenosis. Projectile non-bilious vomiting, dehydration, or hypochloremic alkalosis during or after erythromycin therapy should prompt urgent ultrasound and surgical evaluation — do not attribute to reflux.

6. Agents to Avoid for Routine NICU Reflux or Feeding Residuals

Medication	Why Routine Use Is Discouraged
Metoclopramide	No convincing neonatal efficacy for routine reflux; boxed warning for tardive dyskinesia; pediatric label concerns include extrapyramidal effects and methemoglobinemia risk in neonates.
Domperidone	Not FDA-approved in the United States; FDA reports association with serious cardiac adverse events including arrhythmias, cardiac arrest, and sudden death.
Cisapride	Historical prokinetic with serious QT/arrhythmia concerns; avoid, especially when combined with macrolides or other QT-prolonging medications.
Bethanechol	Limited supportive neonatal evidence and routine use discouraged in Baylor guidance; discuss only with intestinal rehabilitation/GI if considered for exceptional circumstances.
Stacked therapy	Do not combine multiple prokinetics, acid blockers, thickening agents, and feed changes without a clear diagnosis, endpoint, and multidisciplinary plan. Polypharmacy makes adverse effects and diagnostic confusion more likely.

7. Monitoring, Documentation, and Family Communication

Area	What to Document
Indication	Specific dysmotility phenotype; why physiologic reflux/GERD alone is not the indication; what alternatives were excluded.
Objective baseline	Current feeds, calories, route, feed duration, emesis count, gastric/ostomy output, abdominal exam, growth velocity, and respiratory support/events.
Approval and safety	GI/intestinal rehabilitation discussion, pharmacy dose check, interaction review, electrolyte/ECG considerations, and stop date.
Response	Daily change in feed advancement, emesis/output, stooling, weight, abdominal status, and adverse effects.
Parent message	Explain that this is not a standard reflux medicine; it is a short trial for severe motility problems and will be stopped if benefit is not clear or safety concerns arise.
Discharge	Avoid discharge on prokinetic therapy without GI/intestinal rehabilitation follow-up, a refill plan, growth plan, side-effect education, and clear reassessment timing.

Source-difference note

Baylor allows selected use of erythromycin and amoxicillin/clavulanate for significant dysmotility, especially intestinal-failure phenotypes, but emphasizes low-certainty evidence and specialist involvement.
West Midlands and Belize reflux guidance emphasize that pharmacologic therapy, including prokinetics, is not supported for ordinary GORD/GOR in babies.
NASPGHAN/ESPGHAN guidance suggests not using metoclopramide or domperidone for pediatric GERD and not using other prokinetics such as erythromycin or bethanechol as first-line GERD treatment.

8. Suggested Order Note Template

Copy-forward checklist for a safe trial

Indication: clinically significant dysmotility / delayed gastric emptying / intestinal failure, not routine GER.
Excluded: NEC/SIP/obstruction/sepsis/metabolic disease/cow milk protein allergy/dysphagia concern as clinically indicated.
Baseline: feeds ___ mL/kg/day, kcal/oz ___, feed duration ___ min/hr, emesis/output ___, weight trend ___.
Consults: GI/Intestinal Rehabilitation ___; Pharmacy ___; Dietitian/SLP/Surgery if relevant ___.
Medication plan: one agent only, dose ___, start date ___, reassess/stop date ___, target endpoint ___.
Safety plan: review QT/electrolytes/interactions/liver status; monitor abdominal exam, stools, emesis, rhythm, and signs of pyloric stenosis.

When there is no benefit

If the target endpoint is not met by the stop date, discontinue therapy and reassess the underlying diagnosis rather than escalating to a second prokinetic or increasing dose.

Key Takeaways — Chapter 11.4

Promotility agents are not first-line therapy for physiologic GER, apnea of prematurity, ordinary emesis, or non-specific feeding residuals.
Bilious emesis, distension, bloody stool, shock, projectile vomiting, or signs of intestinal emergency must be excluded before any prokinetic is considered.
Metoclopramide and domperidone carry serious safety warnings and should not be used routinely; cisapride is avoided, especially with macrolides.
Erythromycin ethylsuccinate (5–10 mg/kg/dose q6h enterally) is the most defensible agent in selected infants with documented dysmotility after day 14, with specialist and pharmacy approval.
Every trial needs: one drug only, written indication, defined endpoint, stop date, safety checks (QTc, electrolytes, LFTs, drug interactions), and daily monitoring.
Erythromycin carries IHPS risk — projectile non-bilious vomiting during or after therapy requires urgent ultrasound and surgical evaluation.
Do not discharge an infant on a prokinetic without GI/intestinal rehabilitation follow-up, a stop-plan, and caregiver education.

Selected References

Baylor College of Medicine. Guidelines for Acute Care of the Neonate, Edition 33, 2025–2026. Section 6.6: Promotility Agents.
West Midlands Neonatal Operational Delivery Network. Neonatal Guidelines 2025–2028. Gastro-oesophageal reflux disease (GORD).
Belize Ministry of Health. Neonatal Clinical Practice Guidelines 2018–2021. Gastro-oesophageal reflux and nutritional support.
Eichenwald EC; AAP Committee on Fetus and Newborn. Diagnosis and Management of Gastroesophageal Reflux in Preterm Infants. Pediatrics. 2018;142(1):e20181061.
Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: NASPGHAN/ESPGHAN. J Pediatr Gastroenterol Nutr. 2018;66(3):516–554.
Ng E, Shah VS. Erythromycin for the prevention of feeding intolerance in preterm infants. Cochrane Database Syst Rev. CD001815.
DailyMed. Metoclopramide prescribing information — boxed warning: tardive dyskinesia. National Library of Medicine.
DailyMed. Erythromycin ethylsuccinate label — QT, interactions, and IHPS warnings. National Library of Medicine.
FDA. Domperidone information — not FDA-approved; serious cardiac adverse events.

Implementation note

This chapter is designed for education and guideline-building. Bedside use must follow local neonatal formulary, pharmacy compatibility, specialist recommendations, and institutional policy. Dosing should be verified against local drug references and pharmacy before ordering.